Clinical trials: Stage II Breast Carcinoma
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
This trial studies the acceptability and how well decision making tool works in supporting decision making in contralateral prophylactic mastectomy in patients with newly diagnosed breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT02918474
- Testing
- Decision Aid, Questionnaire Administration
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Neoplasms, Endocrine Breast Diseases
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
About a third of patients with breast cancer are usually treated by hormone pills called tamoxifen and aromatase inhibitors. Aromatase inhibitors are drugs that stop female hormone production.
- Conditions
- Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis
- Trial name
- NCT01499160
- Testing
- letrozole, lapatinib, everolimus
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Maryland, Baltimore
Breast Cancer
A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients
Primary objective: To evaluate the disease-free survival (DFS) in the two randomized arms after therapy with LC vs. EC in chemo-naive Her2-patients with stage I or II breast cancer Secondary objectives: To assess the overall…
- Trial name
- NCT01210768
- Testing
- Epirubicin+Cyclophosphamide, liposomal-doxorubicin+Cyclophosphamide
- Where
- 9 sites in Taiwan
- Volunteers
- 254 people
- Sponsor
- TTY Biopharm
Breast Cancer
Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients
The purpose of this study is to determine if a Contura catheter can avoid a radiation "hot spot" in the skin and improve tissue-balloon conformance in early-stage breast cancer patients undergoing accelerated partial breast…
- Trial name
- NCT00882089
- Testing
- Contura catheter
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Cancer Center of Irvine
Breast Cancer
Effect of Advertisements on Treatment Compliance in Women With Breast Cancer
RATIONALE: Measuring how advertising affects treatment compliance in women with breast cancer may help doctors plan the best treatment.
- Trial name
- NCT00462410
- Testing
- counseling intervention, psychosocial assessment and care
- Volunteers
- 65 people
- Sponsor
- Institut Bergonié
Breast Cancer
Preoperative Breast Irradiation
The PROBI is a phase I/II trial assessing the feasibility of preoperative whole breast irradiation in female patients with low to intermediate risk breast cancer, who undergo breast conserving therapy, including a boost dose of…
- Trial name
- PROBI (NCT02941835)
- Testing
- pre-operative irradiation
- Where
- Netherlands
- Volunteers
- 4 people
- Sponsor
- The Netherlands Cancer Institute
Metastatic Breast Cancer
Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA)
This is a prospective two-stage single arm phase II study to be conducted in conformance with Good Clinical Practices. This study will enrol 53 patients, based on a two steps Simon's design.
- Trial name
- NCT03732391
- Testing
- Pembrolizumab 25 MG(milligram)/ML
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- CORTESI LAURA
Breast Cancer
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane, letrozole, or anastrozole, may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00265759
- Testing
- anastrozole, exemestane, letrozole
- Where
- 3 sites in United States
- Volunteers
- 622 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Effect of Drugs, Safety Issues
Remifemin Preventing the Climacteric Symptoms in Breast Cancer
LHRH-a is an important hormone treatment in breast cancer especially in high-risk hormone receptor-positive patients or hormone receptor-negative but needing ovarian function protecting.
- Trial name
- NCT03339882
- Testing
- Remifemin
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Zhejiang Cancer Hospital
Brain Metastases, Breast Cancer
STAR Cape+BKM120 MBC With Brain Met
This is a study to determine the safety and effectiveness of BKM120 plus capecitabine in breast cancer patients with brain metastases. Both capecitabine and BMK120 have previously shown activity in patients with breast cancer.
- Conditions
- Brain Metastases, Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT02000882
- Testing
- BKM120, capecitabine, Trastuzumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- US Oncology Research
Breast Cancer
Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer
To date no targeted agents are available to treat TNBC. Therefore chemotherapy is the only treatment option. TNBC often has a high amount of tumour infiltrating lymphocytes.
- Trial name
- GeparNuevo (NCT02685059)
- Testing
- MEDI4736 (Anti PD-L1), nab-Paclitaxel, Epirubicin
- Where
- Germany
- Volunteers
- 174 people
- Sponsor
- GBG Forschungs GmbH
Metastatic Breast Cancer
Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
The objective of this research is to evaluate the efficacy of the treatment strategy to administer atezolizumab + nab-paclitaxel (PTX) following 2 cycles of induction therapy with PTX + bevacizumab (induction treatment strategy)…
- Trial name
- INDUCE (NCT06793553)
- Testing
- Induction therapy
- Where
- Japan
- Volunteers
- 106 people
- Sponsor
- Japan Breast Cancer Research Group
Breast Cancer
Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00004172
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Sponsor
- Northwestern University
Breast Cancer
Letrozole in Preventing Breast Cancer in Postmenopausal Women
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Letrozole may be effective in preventing the development or recurrence of breast cancer in postmenopausal…
- Trial name
- WISE (NCT00090857)
- Testing
- Letrozole
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Sunitinib malate and exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00931450
- Testing
- exemestane, sunitinib malate
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Institut Català d'Oncologia
HER2-positive, Metastatic Breast Cancer
ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases
A Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose Disease is resistant or refractory to Tyrosine kinase inhibitors (TKI).
- Trial name
- NCT05018702
- Testing
- ARX788
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fudan University
Breast Cancer
Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer
What is the best dosage of Nab-Paclitaxel for chinese? This study would divide patients into two dosage groups: 1) 125mg/m2, 30 minutes intravenous injection, d1, 8, 21 days for a cycle(clinical use); 2) 125mg/m2 d1, 8, 15, 30…
- Trial name
- NCT04192331
- Testing
- nab-paclitaxel regimen1, nab-paclitaxel regimen2
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Peking University Cancer Hospital & Institute
Metastatic (Stage IV) Melanoma
Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
Although treatments for breast cancer have improved, 20-30% of patients with early disease develop metastases (cancer that spreads to other parts of the body).
- Trial name
- EPIBREAST (NCT07340619)
- Testing
- prifetrastat monotherapy for 15 days then combination with fulvestrant, prifetrastat in combination with fulvestrant
- Where
- 8 sites in France
- Volunteers
- 51 people
- Sponsor
- UNICANCER
Breast Cancer
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.
- Trial name
- DTP (NCT03820141)
- Testing
- Durvalumab, Trastuzumab, Pertuzumab
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- The Methodist Hospital Research Institute
Breast Neoplasms
A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.
This is a study to explore how well the combination of LY231514 and Gemcitabine work together in patients with breast cancer that has spread beyond the location of the original tumor.
- Trial name
- NCT00034489
- Testing
- pemetrexed, gemcitabine
- Where
- United States
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.